Skip to content

Research / Diagnostics

Biomarkers

Biomarkers are blood-borne markers of disease that can be used for diagnosis or to measure disease progression and modulation during drug treatment.

Gloved hand holding sample tubes for blood biomarker analysis
Photo: Dr. Rachael A. Dunlop
Section 01The need

Blood-borne biomarkers are urgently needed to aid in the accurate, rapid and inexpensive diagnosis of neurodegenerative diseases, and especially in the early stages when symptoms overlap, and differentiation between conditions is difficult. This is particularly true for ALS, where physicians sometimes must wait for progression of symptoms to definitively identify ALS. This is a problem for patients since survival time averages 2 to 5 years in ALS, and misdiagnosis is very common. Patients are known to undergo invasive and unnecessary medical procedures whilst waiting for a diagnosis, and this contributes to stress and financial and mental hardship.

Diagnosis of most neurodegenerative diseases involves careful clinical assessment combined with various tests, but even so, initial misdiagnosis can be as high as 13 to 63% (in ALS). A simple biomarker blood test could shorten the time to diagnosis, enable patients to access therapies earlier when they are most effective, gain access to experimental treatments as a part of clinical trials, and alleviate financial and mental hardship associated with a serious diagnosis. Taken together, a rapid, accurate and affordable biomarker blood test would significantly improve patient outcomes.

Section 02Our work

Brain Chemistry Labs is currently developing blood-based biomarker tests for ALS and Alzheimer’s disease.

Our ALS test is the furthest along and has been validated in a commercial CLIA/CAP accredited lab as a laboratory-developed test. The test will be available to patients via their medical professional. Our Alzheimer’s disease test is still under development.

The ALS Test

Section 03Future work

Future work involves developing biomarker tests for other neurodegenerative diseases.

Join us in supporting this highly impactful work.

Section 04References
Two tests

ALS, Alzheimer’s

Blood-based biomarker tests. The ALS test is the furthest along; the Alzheimer’s disease test is still under development.

  • ALS TestValidated
  • LabCLIA/CAP accredited
  • Alzheimer’s testIn development
  • NextOther diseases
Biomarker papers
Section 04How a biomarker helps

From a marker to an earlier answer.

A rapid, accurate and affordable biomarker blood test would significantly improve patient outcomes.

Biomarker papers
01WAITING FOR A DIAGNOSISSurvival averages 2 to 5 years;misdiagnosis up to 13 to 63%02A BLOOD-BORNE MARKERDiagnosis, disease progressionand response to drug treatment03THE ALS TESTValidated in a CLIA/CAP labas a laboratory-developed test04THE ALZHEIMER’S TESTStill under development;other diseases to follow